Lactalis
10
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
75.0%
-11.6% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Tolerance and Growth Outcomes of an Extensively Hydrolysed Anti-regurgitation Casein-based Formula in Infants With Cow's Milk Protein Allergy
Role: lead
Glycaemic Index Determination in Oral Nutrition Supplements
Role: collaborator
Evaluation of Gastrointestinal pH and Motility After the Consumption of Milk
Role: lead
Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain
Role: lead
Nutritional Study in Spanish Pediatric Population
Role: collaborator
Effect of a New High-protein Oral Supplement on Functional Parameters in Patients in Nursing Homes
Role: lead
Effect of a Mix of Dairy Lipids and Plant Oils in Infant Formula on Omega-3 Fatty Acid in Red Blood Cells
Role: lead
Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life
Role: lead
Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas
Role: lead
Tolerance and Digestibility of a New Formula in Healthy Infants
Role: lead
All 10 trials loaded